Biomarkers · Cardiac & Hemodynamics
High-Sensitivity Cardiac Troponin T (hs-cTnT)
Lower values go with lower risk of death. No risk curve catalogued yet.
Published risk of death1.31×per 1-SD increase in basal hs-cTnT (cTnT stratum) (95% CI 1.13–1.53) · Meta-analysis of 11 prospective general-population cohorts (65,019 participants overall); estimate is the cTnT stratum
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in hs-cTnT, study by study
2 effects with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| clinical | Choosing off-pump rather than on-pump CABG surgery (peak postoperative hs-cTnT at 6-8 h) | Mean peak hs-cTnT 186 ng/L (95% CI 172 to 200) after off-pump CABG vs 629 ng/L (95% CI 529 to 726) after on-pump CABG | meta-analysis | Heuts S, et al. Am J Cardiol. 2022. Meta-Analysis Evaluating High-Sensitivity… |
Things that worsen it
| Type | Condition or exposure | Reported effect | Evidence | Source |
|---|---|---|---|---|
| clinical | Acute Myocardial Infarction (Type 1 or Type 2 ischemia) | Roche high-sensitive troponin T at presentation diagnosed acute MI with AUC 0.96 (95% CI 0.94 to 0.98) (concentration magnitude not reported) | cross-sectional | Reichlin T, et al. Early diagnosis of myocardial infarction with sensitive… |
| clinical | A single clinical exercise stress test; hs-cTnT measured before and after in patients referred for ischaemia testing | hs-cTnT rises by 1.1 ng/L (18%) after exercise stress testing in patients without inducible ischaemia (0.5 ng/L / 11% with ischaemia) | meta-analysis | Samaha E, et al. J Am Heart Assoc. 2019. High-Sensitivity Cardiac Troponin… |
| pharmacologic | Anthracycline (epirubicin) chemotherapy cardiotoxicity | hs-cTnT rose from median 2.0 to 13.3 ng/L (565% change) by final cycle of epirubicin chemotherapy | prospective cohort | Isemede DA, et al. Assessing the cardiotoxicity of Epirubicin-based… |
What else moves this marker
They describe those study groups, not an individual, and an association is not a cause.
Diseases and conditions
| What | Effect on the marker | Comparison · population | Source |
|---|---|---|---|
| ↑ COVID-19 severity · severe vs non-severe COVID-19 | SMD +0.93 (95% CI 0.21 to 1.65) | severe vs non-severe COVID-19 · COVID-19 inpatients, severity analysis of 7812 patients from 67 studies | meta analysis · PMID 34416596 |
Genetic predisposition
| What | Effect on the marker | Comparison · population | Source |
|---|---|---|---|
| ↕ Common SNP heritability of hs-cTnT · proportion of variance explained by genome-wide SNPs | +10.15% | proportion of hs-cTnT variance explained by SNPs · 24,617 multi-ethnic participants free of CHD and HF from 6 population-based cohorts | gwas · PMID 34732054 |
| ↑ PPFIA4 rs3737882 C allele · per copy of the C allele (MAF 0.18) | +6 percent per allele | per copy of rs3737882 C allele · 24,617 multi-ethnic participants free of CHD and HF from 6 population-based cohorts | gwas · PMID 34732054 |